The counterattack of BSM aims Samjin, United, JW and Ildong
Keeping the top position in prescriptions, Baraclude (BMS) has started to counterattack.
According to the industry concerned, Bristol-Myers Squibb Holdings Island owning the permission of the hepatitis type B treatment, Baraclude, has recently filed an appellate trial for the trial decision agai...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
